BioInvent International have announced that they have signed a clinical trial partnership with Cancer Research UK, Cancer Research Technology, and with Leukaemia and Lymphoma Research. The clinical trial partnership will assess BioInvent’s experimental antibody, BI-1206, in reducing resistance to rituximab treatment in patients with certain blood cancers.
Sweden’s BioInvent International has announced that they have been forced to restructure after the failure of an investigational antithrombotic in a mid-stage trial earlier this month. The corporation will restructure to have 68 permanent workers, in comparison to the present 89 permanent employee. The reduction of the staff “and other reprioritisations” will create cost savings